Pherecydes-Pharma, Theranexus, Telesphore Pharma
Companies Details below
Pherecydes-Pharma, BMSystems’ first therapeutic start-up (2006)

Pherecydes-Pharma: First BMSystems’ therapeutic start-up, ( novel M.R. anti-bacterial nano-agents biotherapies with phages), indications: Multi-resistant infections compassionate use success with natural phages.

CEA/BMSystems exclusive license to Theranexus, a CEA’s spin-off. (2013)

CEA/BMSystems collaborative research in CNS (psychiatric and neurological disorders) led to the co-owned patent WO201029131 with a worldwide exclusive license to Theranexus CEA’s spin-off currently in Phase II.

Telesphore-Pharma, BMSystems’ second therapeutic spin-off (2020)

Telesphore-Pharma: Second BMSystems’ therapeutic spin-off, addresses Chronic Low-Grade Inflammatory Disorders with a First in class treatment for ME/CFS and a group of Post Covid-19 "long-haulers". 
Its first objective is to transform for the first time Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome from a syndrome that lacks concrete diagnostic criteria and treatment, into a universally recognisable, diagnosable and treatable organic disease.